Press "Enter" to skip to content

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.

Morgan is certainly serving as economic advisor to Allergan and Covington & Burling LLP is definitely serving as Allergan's lead lawyer. Goldman Sachs is normally serving as monetary advisor to KYTHERA and Latham & Watkins LLP can be serving as KYTHERA's lead lawyer.. Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion Allergan plc , a leading global pharmaceutical organization, and KYTHERA Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the discovery, commercialization and advancement of novel prescription items for the aesthetic medication market, today announced they have entered right into a definitive agreement under which Allergan has decided to acquire KYTHERA in a cash and equity purchase valued at $75 per KYTHERA share, or approximately $2.1 billion, subject to the fulfillment of particular customary circumstances summarized below.Dr Patel is normally a nationally and internationally recognized liver researcher and was involved in several NIH funded biomedical grants linked to alcoholic liver disease. Dr Patel offers edited biomedical books in the region of nutrition and health prevention, autism, biomarkers and has published over 150 articles.

ADVENTRX prices underwritten public offering of common stock ADVENTRX Pharmaceuticals, Inc. today announced the prices of an underwritten open public providing of 21,250,000 shares of its common share and warrants exercisable for 10,625,000 additional shares at $0.80 per fixed mix of shares and warrants for gross proceeds of around $17 million.5 of a share.10 per share and a 5-year term.